OncoMatch/Clinical Trials/NCT05675787

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Is NCT05675787 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Medroxyprogesterone acetate + Atorvastatin for atypical endometrial hyperplasia.

Phase 2RecruitingPeking University People's HospitalNCT05675787Data as of May 2026

Treatment: Medroxyprogesterone acetate + Atorvastatin — To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Disease stage

Required: Stage I

Grade: g1

Prior therapy

Min 0 prior lines

Must have received: progesterone therapy — persistent lesions after one course (12 weeks) OR incomplete remission after 2 courses (24 weeks)

Patients with persistent lesions after one course (12 weeks) of progesterone therapy; Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify